Search for
Testis - Large Biopsy 3-6 cm
Biopsy
Report in 288Hrs
At Home
No Fasting Required
Details
Biopsy of testicular tissue.
₹666₹951
30% OFF
Testis - Large Biopsy 3-6 cm
- Why is it done?
- Test Purpose: A large testicular biopsy (3-6 cm) is a surgical procedure that removes a substantial tissue specimen from the testis to obtain comprehensive histopathological diagnosis and tissue analysis for suspected testicular malignancies or other significant pathological conditions.
- Primary Indications: Suspected testicular cancer (germ cell tumors, seminomas, non-seminomatous germ cell tumors); evaluation of testicular masses or lesions; assessment of abnormal testicular imaging findings; diagnosis of primary testicular lymphoma; evaluation of persistent testicular abnormalities after ultrasound findings
- Typical Timing: Performed when imaging studies (ultrasound, MRI, or CT) reveal suspicious testicular lesions; typically following abnormal tumor markers or clinical examination findings; often performed urgently when malignancy is suspected due to the aggressive nature of testicular cancers
- Normal Range
- Normal Histopathology: Normal testicular tissue shows intact seminiferous tubules with organized spermatogenic cells (spermatogonia, primary spermatocytes, round spermatids, elongated spermatids); preserved basement membrane; normal Leydig cells in interstitium; absence of malignant cells or atypical germ cell proliferation
- Result Interpretation: Negative/Benign = No malignant cells identified, tissue architecture preserved, normal spermatogenesis present; Positive/Abnormal = Presence of malignant cells, germ cell tumor identified, atypical hyperplasia, or other significant pathology; Borderline = Atypical germ cell neoplasia in situ (GCNIS), which carries high risk of progression to invasive malignancy
- Units of Measurement: Specimen size measured in centimeters (3-6 cm tissue core); histological findings reported using standardized pathological classification systems (TNM staging, WHO classification for testicular tumors); mitotic count expressed as number of mitoses per 10 high-power fields
- Normal vs Abnormal Meaning: Normal results indicate benign pathology, rule out malignancy, and may show benign conditions (fibrosis, atrophy, inflammation); abnormal results confirm malignancy diagnosis, guide staging and treatment selection, and have significant prognostic implications; findings directly influence surgical approach (orchidectomy vs testis-sparing surgery) and systemic therapy decisions
- Interpretation
- Benign Findings: Absence of malignant cells with normal histology; indicates no cancer present; may reveal benign conditions such as testicular atrophy, fibrosis, chronic inflammation, or lymphocytic infiltration; rules out malignancy as source of imaging abnormality; typically allows testis-preserving management approaches
- Malignant Findings - Germ Cell Tumors: Seminoma (most common, ~40% of cases): Single cell type, uniform appearance, sensitive to chemotherapy and radiation; Non-seminomatous germ cell tumors (embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, mixed): Multiple cell types, higher mitotic activity, more aggressive behavior; presence of GCNIS carries ~70% risk of progression to invasive cancer within 5 years
- Primary Testicular Lymphoma: Usually diffuse large B-cell lymphoma (DLBCL); accounts for 1-2% of testicular cancers; typically affects older men; requires different treatment approach than germ cell tumors; often presents with bilateral involvement
- Factors Affecting Interpretation: Specimen adequacy and size (larger biopsies provide better representation); tumor heterogeneity (different cell types may vary within lesion); sampling location within lesion; patient age and risk factors; associated tumor markers (AFP, beta-hCG); imaging characteristics; clinical presentation and symptom duration
- Clinical Significance - Prognostic Indicators: Tumor type and histological subtype directly determine treatment regimen; mitotic rate and necrosis indicate aggressive behavior; lymphovascular invasion predicts spread potential; presence of GCNIS requires contralateral testis surveillance; combination of biopsy findings with tumor markers guides staging and prognosis; histology influences chemotherapy sensitivity and long-term survival outcomes
- Associated Organs
- Primary Organ System: Male reproductive system (testis, epididymis, spermatic cord); endocrine system (testosterone production); genital/urological system
- Commonly Associated Pathological Conditions: Testicular seminomas and non-seminomatous germ cell tumors; primary testicular lymphoma; testicular metastases from other primary cancers; benign testicular masses (lipomas, fibromas, adenomatoid tumors, cystic lesions); testicular atrophy and fibrosis; chronic orchitis and granulomatous inflammation; spermatogenic arrest
- Diseases This Test Helps Diagnose: Testicular cancer (most common solid malignancy in males aged 15-35 years); germ cell tumors (90% of testicular cancers); sex cord-stromal tumors (Leydig cell, Sertoli cell tumors); secondary malignancies involving testis; testicular involvement in systemic lymphoma
- Potential Complications and Risks: Hemorrhage and hematoma formation; infection and orchitis; damage to spermatic cord and vessels; testicular atrophy from vascular compromise; chronic pain or post-procedure discomfort; infertility if bilateral testis involvement; delayed diagnosis if biopsy is non-diagnostic; tumor seeding along biopsy tract (rare but possible); anesthesia-related complications; need for subsequent radical orchidectomy if malignancy confirmed
- Related Organ Effects: Malignant findings may indicate metastatic potential to regional lymph nodes (retroperitoneal), lungs (most common distant site), brain, liver, and bones; bilateral testicular involvement occurs in ~10% of germ cell tumors; contralateral testis carries GCNIS risk; systemic effects include hypogonadism, erectile dysfunction, and infertility from disease or treatment
- Follow-up Tests
- If Malignancy Confirmed: Radical inguinal orchidectomy with high ligation of spermatic cord; staging computed tomography (CT) of chest, abdomen, and pelvis; tumor marker evaluation (serum alpha-fetoprotein, beta-human chorionic gonadotropin, lactate dehydrogenase); positron emission tomography (PET) scan if indicated; contralateral testis ultrasound and possible biopsy for GCNIS assessment; retroperitoneal lymph node dissection if indicated by stage
- If Benign Pathology: Repeat ultrasound imaging at 3-6 months if residual imaging abnormality; clinical follow-up for symptom resolution; testicular preservation and standard fertility counseling; surveillance imaging if inflammatory or atypical findings present; baseline sperm analysis if fertility concerns; testosterone level assessment if atrophy noted
- If GCNIS Identified: Bilateral testis ultrasound and possible contralateral biopsy; discussion of surveillance versus radiotherapy options; regular clinical and imaging surveillance; biannual to annual ultrasound for 5 years minimum; patient education on cancer risk and symptom recognition; sperm banking before any treatment
- Monitoring Frequency for Active Disease: Clinical examination every 4-6 weeks during active treatment; imaging surveillance every 8-12 weeks during chemotherapy; tumor marker assessment (AFP, beta-hCG) at regular intervals during treatment; post-treatment surveillance: monthly for first 6 months, then every 3 months for years 1-2, then every 6 months for year 3, then annually for years 4-5, then as clinically indicated
- Complementary Tests: Ultrasound of contralateral testis (assess for occult disease); genetic testing (Klinefelter syndrome, familial predisposition); immunohistochemistry on biopsy (confirm tumor type, prognosis); cytogenetics/chromosomal analysis (gain chromosome 12p); flow cytometry if lymphoma suspected; semen analysis and sperm banking before treatment; psychosocial assessment and fertility counseling
- Fasting Required?
- Fasting Status: Yes - fasting is typically required due to use of general or regional anesthesia for this surgical procedure
- Fasting Duration: Minimum 6-8 hours of NPO (nothing by mouth) prior to procedure; typically 8 hours for solid food and milk; 2-3 hours for clear liquids (per anesthesia protocol); exact requirements determined by anesthesia team at pre-operative assessment
- Medications to Avoid: Anticoagulants (warfarin, apixaban, rivaroxaban) - typically held 3-5 days pre-procedure; antiplatelet agents (aspirin, clopidogrel) - hold 5-7 days before surgery; NSAIDs - hold 5-7 days pre-procedure; herbal supplements with anticoagulant properties (ginkgo biloba, garlic, ginseng); confirm with surgeon and anesthesiologist which medications to continue or discontinue
- Other Patient Preparation Requirements: Complete pre-operative laboratory testing (CBC, BMP, coagulation studies, urinalysis); EKG and chest X-ray if indicated by age/medical history; history and physical examination; informed consent discussion including risks and alternatives; NPO status confirmation evening before procedure; arrange transportation as driving is prohibited post-anesthesia; shower/bathe with antibacterial soap morning of procedure; remove all jewelry, piercings, dentures, contact lenses; wear comfortable, loose clothing; empty bladder before pre-medication; discuss any drug allergies or previous anesthetic complications
- Post-Procedure Instructions: Take medications as prescribed; resume diet as tolerated after anesthesia recovery; apply ice to surgical site (15 minutes on, 15 minutes off) for first 48 hours; wear scrotal support/athletic supporter for comfort; limit physical activity and heavy lifting for 1-2 weeks; avoid strenuous exercise and sexual activity until cleared by physician (typically 1-2 weeks); watch for signs of infection (fever, increasing pain, discharge); take prescribed antibiotics if given; pain management with prescribed analgesics; monitor incision for bleeding, swelling, or separation
How our test process works!
